Integra LifeSciences Holdings Corporation (IART)

NASDAQ: IART · IEX Real-Time Price · USD
67.44 -1.35 (-1.96%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap5.71B
Revenue (ttm)1.53B
Net Income (ttm)216.44M
Shares Out84.70M
EPS (ttm)2.54
PE Ratio26.55
Forward PE18.48
Dividendn/a
Ex-Dividend Daten/a
Volume406,591
Open67.99
Previous Close68.79
Day's Range67.04 - 68.30
52-Week Range61.85 - 77.40
Beta1.20
AnalystsBuy
Price Target77.82 (+15.4%)
Earnings DateNov 2, 2021

About IART

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial...

IndustryHealth Care Equipment & Supplies
IPO DateAug 16, 1995
CEOPeter Arduini
Employees3,700
Stock ExchangeNASDAQ
Ticker SymbolIART
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 77.82, which is an increase of 15.39% from the latest price.

Price Target
$77.82
(15.39% upside)
Analyst Consensus: Buy

News

Integra (IART) Announces Preliminary Q4 & '21 Sales Results

Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.

5 days ago - Zacks Investment Research

Integra LifeSciences Reports Interim Q4 Sales Marginally Ahead Of Expectations

Integra LifeSciences Holdings Corp (NASDAQ: IART) expects Q4 FY21 sales of $404 million - $406 million, representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basis. I...

1 week ago - Benzinga

5 Stocks To Watch For January 12, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Shaw Communications Inc. (NYSE: SJR) to report quarterly earnings at $0.29 per share on revenue of $1.10 billion before the...

Other symbols:ALLYKBHSJRWIT
1 week ago - Benzinga

Integra LifeSciences Reports Preliminary Fourth Quarter and Full-Year 2021 Revenue and Plans $125 Million Share Repur...

PRINCETON, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fo...

1 week ago - GlobeNewsWire

Here's Why You Should Hold on to Integra (IART) Stock for Now

Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.

3 weeks ago - Zacks Investment Research

Integra (IART) Businesses Rebound Despite Supply Issues

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

4 weeks ago - Zacks Investment Research

Integra (IART) Down 13.2% Since Last Earnings Report: Can It Rebound?

Integra (IART) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

2 months ago - Zacks Investment Research

Integra LifeSciences Stock Rises On Street-Beating Q3 Earnings, Raises FY21 EPS Guidance

Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares got a boost as Q3 adjusted EPS of $0.86 topped the consensus forecast of $0.72. Revenues increased 4.5% Y/Y (6.7% organically) to $386.9 m...

2 months ago - Benzinga

Integra LifeSciences (IART) Q3 Earnings and Revenues Top Estimates

Integra (IART) delivered earnings and revenue surprises of 19.44% and 0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Integra LifeSciences Reports Third Quarter 2021 Financial Results

Third Quarter 2021 Highlights

2 months ago - GlobeNewsWire

Integra LifeSciences Announces Jan De Witte as President and Chief Executive Officer

30-year healthcare and technology veteran with extensive global executive experience and diverse expertise in R&D, commercialization, product management, digital innovation and operations 30-year health...

2 months ago - GlobeNewsWire

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Integra LifeSciences to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2021 financial result...

3 months ago - GlobeNewsWire

Integra LifeSciences Announces Participation in Upcoming Investor Conferences

PRINCETON, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the...

4 months ago - GlobeNewsWire

Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?

Integra (IART) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

Here's Why You Should Retain Integra (IART) Stock for Now

Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).

4 months ago - Zacks Investment Research

Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

5 months ago - Zacks Investment Research

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

5 months ago - Zacks Investment Research

Integra's Update On FY21 Acell Revenues To Weigh On Stock, Piper Sandler Says

Piper Sandler has raised the price target on Integra LifeSciences Holding Corporation (NASDAQ:IART) to $72 from $70 and reiterated a Neutral rating following the Q2 beat.  The company posted Q2 EPS of $...

5 months ago - Benzinga

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Integra Lifesciences Q2 Earnings

Shares of Integra Lifesciences (NASDAQ:IART) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 139.39% over the past year to $0.79, which beat the esti...

5 months ago - Benzinga

Integra LifeSciences Reports Second Quarter 2021 Financial Results

Raises Full-Year 2021 Guidance Raises Full-Year 2021 Guidance

5 months ago - GlobeNewsWire

Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Integra (IART) Releases Favorable PriMatrix Clinical Outcome

Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.

5 months ago - Zacks Investment Research